Application of Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis: a Comparative Analysis of Efficacy and Safety Versus Traditional Treatments

EasyChair Preprint 14754

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation and joint destruction, leading to significant morbidity. Traditional treatments, including disease-modifying antirheumatic drugs (DMARDs), have been the cornerstone of RA management, but they often fall short in achieving sustained remission and are associated with various side effects. In recent years, Janus Kinase (JAK) inhibitors have emerged as a novel class of targeted therapies, offering new hope for patients who do not respond adequately to conventional treatments.This review provides a comprehensive analysis of the efficacy and safety of JAK inhibitors in the treatment of RA, comparing them with traditional therapies such as methotrexate and biologic DMARDs. The article examines clinical trial data, real-world evidence, and meta-analyses to assess the effectiveness of JAK inhibitors in reducing disease activity, slowing radiographic progression, and improving patient-reported outcomes. Furthermore, it explores the safety profile of JAK inhibitors, with a focus on the risk of infections, malignancies, and cardiovascular events, comparing these risks to those associated with conventional treatments.

Keyphrases: Disease Modifying Antirheumatic Drugs (DMARDs), Efficacy, JAK Inhibitors, Rheumatoid Arthritis, Safety Profile, adverse events, comparative analysis, personalized medicine, targeted therapies, treatment outcomes

@booklet{EasyChair:14754,
  author    = {Kayode Sheriffdeen},
  title     = {Application of Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis: a Comparative Analysis of Efficacy and Safety Versus Traditional Treatments},
  howpublished = {EasyChair Preprint 14754},
  year      = {EasyChair, 2024}}